ImmunityBio (NASDAQ:IBRX) Upgraded at BTIG Research

BTIG Research upgraded shares of ImmunityBio (NASDAQ:IBRX) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. D. Boral Capital reissued a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a report on Monday, March 9th. Jefferies Financial Group boosted their price target on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.40.

ImmunityBio Trading Up 7.3%

Shares of IBRX opened at $8.39 on Wednesday. The company’s 50 day simple moving average is $6.62 and its 200-day simple moving average is $3.82. The firm has a market cap of $8.63 billion, a PE ratio of -22.08 and a beta of -0.03. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. As a group, equities research analysts forecast that ImmunityBio will post -0.92 EPS for the current fiscal year.

Insider Activity

In other news, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of the stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the transaction, the director directly owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 501,967 shares of company stock worth $4,466,412. Insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

A number of large investors have recently modified their holdings of IBRX. Slow Capital Inc. acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at approximately $25,000. Truist Financial Corp purchased a new stake in shares of ImmunityBio in the third quarter valued at approximately $27,000. Swiss Life Asset Management Ltd acquired a new position in ImmunityBio during the third quarter worth $27,000. WealthPlan Investment Management LLC purchased a new position in ImmunityBio in the fourth quarter worth $27,000. Finally, Diversify Advisory Services LLC purchased a new position in ImmunityBio in the second quarter worth $27,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Anktiva approvals and sales growth are driving upside expectations — Zacks highlights recent approvals, growing U.S. uptake and global launches that set up a pivotal 2026 for Anktiva. IBRX Stock: Anktiva’s Approvals and What Comes Next
• Positive Sentiment: Company may benefit from a persistent BCG shortage that could accelerate Anktiva adoption in NMIBC; Zacks flags upcoming 2026 catalysts (FDA discussions, global launches, clinical milestones). IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Positive Sentiment: Operational progress: Benzinga reports ImmunityBio completed manufacturing engineering programs for its NK-cell therapy platform — a milestone that could ease scale-up and broaden pipeline value. Why Is ImmunityBio Stock Soaring On Friday?
• Positive Sentiment: Sell-side support: BTIG initiated coverage with a Buy and $13 price target, signaling analyst confidence in further upside from current levels. Benzinga
• Neutral Sentiment: Market narrative: MarketBeat/Barron’s coverage places ImmunityBio among small biotechs benefiting from powerful oncology launches (Anktiva), underscoring both growth potential and sector risk. Why 2 Small Biotechs May Hold the Key to New Cancer Treatments (IBRX)
• Negative Sentiment: Valuation and concentration risks: Zacks flags that the rally has pushed IBRX to roughly 33x sales for Anktiva and notes the premium assumes near-perfect commercialization; reliance on one product and a large 2025 net loss are key risk points. ImmunityBio Valuation: Paying 33x Sales for Anktiva

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.